Please use this identifier to cite or link to this item: https://hdl.handle.net/1/1892
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBack, Michael-
dc.contributor.otherWijetunga, A.-
dc.contributor.otherJayamanne, Dasantha-
dc.contributor.otherCook, R.-
dc.contributor.otherParkinson, J.-
dc.contributor.otherLittle, N.-
dc.contributor.otherCurtis, J.-
dc.contributor.otherBrown, C.-
dc.date.accessioned2020-11-15T23:26:11Z-
dc.date.available2020-11-15T23:26:11Z-
dc.date.issued2020-12-
dc.identifier.citation82(Pt A)155-161en
dc.identifier.issn09675868en
dc.identifier.urihttps://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1892-
dc.description.abstractAbstract Background Following surgical resection of oligometastatic disease to the brain there is a high rate of local relapse which is reduced by the addition of focal radiation therapy, often delivered as single fraction stereotactic radiosurgery (SRS) to the surgical cavity. This study audited the outcomes of an alternative approach using hypofractionated radiation therapy (HFRT) to the surgical resection cavity. Methods and Materials Seventy-nine patients who received surgical resection and focal radiation therapy to the surgical cavity using HFRT with intensity modulated radiation therapy with or without stereotactic radiotherapy were identified. Doses were delivered in five fractions every second day for 10 days. Follow-up involved MRI surveillance with three-monthly MRI scans post resection. The major endpoints were local control at the surgical cavity site, and presence of radiation necrosis at the treated site. Results Seventy-nine patients were included for the analysis with a median follow-up of 10.8 months. Of the cohort, 56% experienced intracranial progression, with all patients progressing distant to the resection cavity, and 7% progressing locally in addition. The one-year local control rate was 89.8%. The median progression-free survival was 10.0 months and median overall survival was 14.3 months. There was one CTCAE grade 3 toxicity of symptomatic radiation necrosis with no grade 4–5 toxicities seen. Conclusions The rate of local relapse following HFRT to the surgical cavity is low with minimal risk of radiation necrosis. HFRT can be considered as an alternative to SRS for focal radiotherapy after brain metastasis resection.en
dc.description.sponsorshipCentral Coast Cancer Centreen
dc.description.sponsorshipRadiation Oncologyen
dc.subjectRadiotherapyen
dc.subjectCanceren
dc.titleHypofractionated adjuvant surgical cavity radiotherapy following resection of limited brain metastasisen
dc.typeJournal Articleen
dc.identifier.doi10.1016/j.jocn.2020.10.041en
dc.description.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/33317725/en
dc.description.affiliatesCentral Coast Local Health Districten
dc.description.affiliatesGosford Hospitalen
dc.identifier.journaltitleJournal of Clinical Neuroscienceen
dc.relation.orcidhttp://orcid.org/0000-0003-2363-8333en
dc.originaltypeTexten
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
crisitem.author.deptRadiation Oncology-
Appears in Collections:Oncology / Cancer
Radiology
Show simple item record

Page view(s)

88
checked on Sep 29, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.